Uganda launches Phase Ib clinical trials for Bundibugyo Ebola vaccine

Phase Ib clinical trials for a candidate vaccine against the Bundibugyo Ebola virus (BDBV) have officially commenced in Uganda. According to the Africa Centers for Disease Control and Prevention (Africa CDC), the trials for the ChAdOx1 BDBV vaccine began on October 6. Developed by the University of Oxford, this candidate vaccine is being tested for safety and immune response following the successful completion of Phase Ia trials previously conducted in Britain.

The Oxford vaccine is part of a broader effort to expand the medical arsenal against various Ebola strains. Uganda has also granted ethical approval for clinical trials of a second candidate vaccine developed by Moderna. The Moderna vaccine had its initial testing phases in Canada before receiving the green light for the Ugandan study. These dual developments signify an intensified research push to provide targeted protection against the Bundibugyo strain, which is distinct from the more common Zaire strain.

The commencement of these trials comes at a critical time as the neighboring Democratic Republic of Congo (DRC) struggles with a severe Ebola outbreak. As of early October, the DRC has recorded 8,728 confirmed cases and 4,205 deaths. Although the DRC has received approximately 70,000 doses of the Ervebo vaccine to manage the crisis, health officials noted that Ervebo is not specifically effective against the Bundibugyo virus, making the Ugandan research essential for regional biosecurity.

Health experts view these clinical trials as a vital step toward establishing a robust defense against future outbreaks in East and Central Africa. By conducting the Phase Ib studies in a region historically impacted by the virus, researchers aim to gather more relevant data on the vaccine's efficacy within the local population. If successful, these candidates could eventually lead to the first licensed vaccines specifically designed to neutralize the Bundibugyo variant of the disease.